The relevant information included in this section is exactly as published on the website of the National Securities Market Commission (CNMV)

Filter results
Date Title PDF
20/09/2018 ROVI announces an agreement with Biogaran for the marketing of its enoxaparin biosimilar in France
19/09/2018 ROVI has commenced the marketing of its enoxaparin biosimilar in Spain
27/07/2018 Enervit exercises the purchase option on 1% of Enervit Nutrition, a joint venture between ROVI and Enervit
26/07/2018 2018 First Quarter results press release
12/06/2018 ROVI announces the agreement with Sandoz to distribute and market its Enoxaparin biosimilar
25/04/2018 2018 First Quarter results press release
24/04/2018 ROVI announces the agreement with Hikma to distribute and market its Enoxaparin biosimilar
31/03/2018 Awarded a grant for the definition of the design space by the appliation of QbD methodology for ISM® formulations
20/02/2018 2017 Results press release
20/02/2018 2017 Results presentation